Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Valproic acid | Tetracosactide may increase the hepatotoxic activities of Valproic acid. |
| Lorazepam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Lorazepam. |
| Pregabalin | The risk or severity of liver damage can be increased when Tetracosactide is combined with Pregabalin. |
| Butalbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Butalbital. |
| Phenytoin | Tetracosactide may increase the hepatotoxic activities of Phenytoin. |
| Topiramate | The risk or severity of liver damage can be increased when Tetracosactide is combined with Topiramate. |
| Pentobarbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Pentobarbital. |
| Trimethadione | The risk or severity of liver damage can be increased when Tetracosactide is combined with Trimethadione. |
| Clobazam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Clobazam. |
| Secobarbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Secobarbital. |
| Metharbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Metharbital. |
| Methohexital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Methohexital. |
| Mephenytoin | The risk or severity of liver damage can be increased when Tetracosactide is combined with Mephenytoin. |
| Lamotrigine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Lamotrigine. |
| Carbamazepine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Carbamazepine. |
| Ethosuximide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Ethosuximide. |
| Thiopental | The risk or severity of liver damage can be increased when Tetracosactide is combined with Thiopental. |
| Paramethadione | The risk or severity of liver damage can be increased when Tetracosactide is combined with Paramethadione. |
| Clorazepic acid | The risk or severity of liver damage can be increased when Tetracosactide is combined with Clorazepic acid. |
| Magnesium sulfate | The risk or severity of liver damage can be increased when Tetracosactide is combined with Magnesium sulfate. |
| Tizanidine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Tizanidine. |
| Riluzole | The risk or severity of liver damage can be increased when Tetracosactide is combined with Riluzole. |
| Ethotoin | The risk or severity of liver damage can be increased when Tetracosactide is combined with Ethotoin. |
| Oxcarbazepine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Oxcarbazepine. |
| Primidone | The risk or severity of liver damage can be increased when Tetracosactide is combined with Primidone. |
| Acetazolamide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Acetazolamide. |
| Diazepam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Diazepam. |
| Phensuximide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Phensuximide. |
| Progabide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Progabide. |
| Methylphenobarbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Methylphenobarbital. |
| Tiagabine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Tiagabine. |
| Zonisamide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Zonisamide. |
| Felbamate | The risk or severity of liver damage can be increased when Tetracosactide is combined with Felbamate. |
| Zaleplon | The risk or severity of liver damage can be increased when Tetracosactide is combined with Zaleplon. |
| Gabapentin | The risk or severity of liver damage can be increased when Tetracosactide is combined with Gabapentin. |
| Vigabatrin | The risk or severity of liver damage can be increased when Tetracosactide is combined with Vigabatrin. |
| Phenacemide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Phenacemide. |
| Thiamylal | The risk or severity of liver damage can be increased when Tetracosactide is combined with Thiamylal. |
| Phenobarbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Phenobarbital. |
| Levetiracetam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Levetiracetam. |
| Estazolam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Estazolam. |
| Fosphenytoin | Tetracosactide may increase the hepatotoxic activities of Fosphenytoin. |
| Amobarbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Amobarbital. |
| Hexobarbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Hexobarbital. |
| Barbital | The risk or severity of liver damage can be increased when Tetracosactide is combined with Barbital. |
| Delorazepam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Delorazepam. |
| 7-Nitroindazole | The risk or severity of liver damage can be increased when Tetracosactide is combined with 7-Nitroindazole. |
| Valpromide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Valpromide. |
| Flunarizine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Flunarizine. |
| Ezogabine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Ezogabine. |
| Methsuximide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Methsuximide. |
| Brivaracetam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Brivaracetam. |
| Rufinamide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Rufinamide. |
| Lacosamide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Lacosamide. |
| Remacemide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Remacemide. |
| Clomethiazole | The risk or severity of liver damage can be increased when Tetracosactide is combined with Clomethiazole. |
| Deramciclane | The risk or severity of liver damage can be increased when Tetracosactide is combined with Deramciclane. |
| Tramiprosate | The risk or severity of liver damage can be increased when Tetracosactide is combined with Tramiprosate. |
| Gaboxadol | The risk or severity of liver damage can be increased when Tetracosactide is combined with Gaboxadol. |
| Sulthiame | The risk or severity of liver damage can be increased when Tetracosactide is combined with Sulthiame. |
| Perampanel | The risk or severity of liver damage can be increased when Tetracosactide is combined with Perampanel. |
| Ifenprodil | The risk or severity of liver damage can be increased when Tetracosactide is combined with Ifenprodil. |
| Barbexaclone | The risk or severity of liver damage can be increased when Tetracosactide is combined with Barbexaclone. |
| Beclamide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Beclamide. |
| Cannabidiol | The risk or severity of liver damage can be increased when Tetracosactide is combined with Cannabidiol. |
| Paraldehyde | The risk or severity of liver damage can be increased when Tetracosactide is combined with Paraldehyde. |
| Stiripentol | The risk or severity of liver damage can be increased when Tetracosactide is combined with Stiripentol. |
| Eslicarbazepine acetate | The risk or severity of liver damage can be increased when Tetracosactide is combined with Eslicarbazepine acetate. |
| Doramectin | The risk or severity of liver damage can be increased when Tetracosactide is combined with Doramectin. |
| Tiletamine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Tiletamine. |
| Brexanolone | The risk or severity of liver damage can be increased when Tetracosactide is combined with Brexanolone. |
| Etiracetam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Etiracetam. |
| Vinpocetine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Vinpocetine. |
| Carisbamate | The risk or severity of liver damage can be increased when Tetracosactide is combined with Carisbamate. |
| Pheneturide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Pheneturide. |
| Neocitrullamon | The risk or severity of liver damage can be increased when Tetracosactide is combined with Neocitrullamon. |
| Medazepam | The risk or severity of liver damage can be increased when Tetracosactide is combined with Medazepam. |
| Phenibut | The risk or severity of liver damage can be increased when Tetracosactide is combined with Phenibut. |
| Ethadione | The risk or severity of liver damage can be increased when Tetracosactide is combined with Ethadione. |
| Cannabidivarin | The risk or severity of liver damage can be increased when Tetracosactide is combined with Cannabidivarin. |
| Eslicarbazepine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Eslicarbazepine. |
| JNJ-26489112 | The risk or severity of liver damage can be increased when Tetracosactide is combined with JNJ-26489112. |
| Cenobamate | The risk or severity of liver damage can be increased when Tetracosactide is combined with Cenobamate. |
| Clonazepam | Tetracosactide may increase the hepatotoxic activities of Clonazepam. |
| Nitrazepam | The serum concentration of Nitrazepam can be increased when it is combined with Tetracosactide. |
| Fenfluramine | The risk or severity of liver damage can be increased when Tetracosactide is combined with Fenfluramine. |
| Ganaxolone | The risk or severity of liver damage can be increased when Tetracosactide is combined with Ganaxolone. |